



Biotech Daily

Tuesday August 12, 2025

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: UNIVERSAL BIOSENSORS UP 14%; ATOMO DOWN 10%**
- * **ANTERIS H1 REVENUE DOWN 16% TO \$1.8m; LOSS UP 23% TO \$66m**
- * **RECCE: 'R327G HIGHLY EFFECTIVE FOR BURN WOUNDS, IN RATS'**
- * **AUDEARA, EASTECH CHINA HEARING PRODUCT LICENCE**
- * **ANTEOTECH, KANGSHIN SOUTH KOREA BATTERY DEAL**
- * **OPYL SIGNS INNOVATRIX FOR CLINICAL TRIAL INSURANCE**
- * **ARCHER, IMEC DEVELOP BLOOD POTASSIUM SENSOR**
- * **NEURIZON MANUFACTURES 1st NUZ-001 REGISTRATION BATCH**
- * **TRYPTAMINE TAKES \$2.6m ROCKFORD RDTI LOAN**

MARKET REPORT

The Australian stock market was up 0.41 percent on Tuesday August 12, 2025, with the ASX200 up 36.0 points to 8,880.8 points.

Sixteen of the Biotech Daily Top 40 companies were up, 13 fell and 11 traded unchanged.

Universal Biosensors was the best, up 0.3 cents or 14.3 percent to 2.4 cents, with 9,087 shares traded. Resonance and Syntara climbed more than seven percent; Avita and Botanix were up more than six percent; Medical Developments and Starpharma improved more than four percent; Cyclopharm and Genetic Signatures were up more than three percent; Aroa rose 2.5 percent; Medadvisor, Micro-X, Neuren and Resmed were up more than one percent; with Clinuvel, Cochlear, CSL, Orthocell and SDI up by less than one percent.

Atomo led the falls, down 0.2 cents or 10.0 percent to 1.8 cents, with 4.4 million shares traded. Clarity lost 8.0 percent; 4D Medical and Paradigm fell more than six percent; Curvebeam and Optiscan were down more than three percent; Nanosonics, Prescient and Proteomics shed two percent or more; Dimerix, Emvision, Polynovo and Telix were down one percent or more; with Pro Medicus down by 0.5 percent.

ANTERIS TECHNOLOGIES GLOBAL CORP

Anteris says revenue for the six months to June 30, 2025 was down 16.0 percent to \$US1,174,000 (\$A1,803,000), with net loss after tax up 22.9 percent to \$US42,993,000 (\$A66,010,000).

Last year, Anteris said it had revenue of about \$A2.1 million for the six months to June 30, 2024 from its bovine cardiac tissue product sales.

Today, the company said its cash outflows were "in line with the increase in ... [costs] to support the 'Paradigm' trial" of its Duravr transcatheter heart valve.

Anteris said research and development expenses rose 35.6 percent to \$US32,796,000, selling, general and administrative costs fell 15.7 percent to \$US10,687,000 and costs of products sold were down 54.8 percent to \$US355,000.

The company said its six months diluted loss per share was \$US1.18, with cash and equivalents of \$US28,438,000 at June 30, compared to \$US10,844,340 the prior year.

Anteris did not disclose net tangible assets per share for the six months, with net tangible assets per share of 19 cents in the prior corresponding period.

Anteris fell 20 cents or 3.5 percent to \$5.45.

RECCE PHARMACEUTICALS

Recce says its R327G topical gel is "highly effective against methicillin-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa* infected burn wounds" in rats.

Recce said its synthetic anti-infective R327G gel had shown "statistically positive efficacy against two clinically significant antibiotic-resistant pathogens [methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa*] including statistically significant wound healing/wound contraction data for burn wounds in rat infection models".

The company said the study assessed R327G gel against the two resistant pathogens, which were in the World Health Organization's list of drug-resistant bacteria most threatening to human health and the most common bacteria isolated from chronic wounds.

Recce said R327G gel led to a "statistically significant reduction in bacterial load compared to untreated control groups, with bacterial counts reduced substantially by day four and highly significant reductions observed by day eight".

The company said the reductions corresponded to about 99 percent at day-4 and a 99.9 percent reduction at day-8 against MRSA and about a 99.9 percent and 99.99 percent reduction against *Pseudomonas aeruginosa* at day-4 and day-8, respectively.

Recce said that "the anti-microbial performance of R327G consistently exceeded that of Soframycin, a standard comparator antibiotic used in topical wound care".

The company said R327G gel further improved the rate of wound healing, as measured by wound contraction, with wounds treated exhibiting "accelerated contraction, with statistically significant improvements".

Recce said the healing outcomes were "consistently superior to both the untreated and Soframycin-treated groups", with R327G gel well-tolerated and no adverse clinical signs of adverse effects on body weight observed in the treated animals.

The company said the study was part of a broader burn wound program supported by a \$US2 million grant and a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases (BD: Jul 15, 2024).

Recce managing-director James Graham said the results were "a further step forward for our US [Department of Defence] burn wound program".

"R327G not only demonstrated superior antimicrobial performance but also promoted significantly faster healing of burn wounds," Mr Graham said.

Recce was up half a cent or 1.2 percent to 41.5 cents.

AUDEARA

Audeara says it will licence its hearing products to the Cayman Islands and Taipei, Taiwan-based Eastech Holding to support commercialization in China.

Audeara said Eastech had an agreement with a third-party purchaser for medical devices using its technology, the devices would be sold under a third-party brand and were expected to be sold online in China.

The company said the deal was “the beginning of a strategic multi-party collaboration that establishes a strong foundation for future product development and commercial growth in China’s hearing health market”.

Audeara said that under the five-year licence it would receive royalties per unit sold, with no minimum purchase obligations and that the financial impact would “depend on commercial success and product uptake”.

Audeara managing-director Dr James Fielding said the deal was “a major milestone in Audeara’s global expansion”.

“The alignment between Audeara, Eastech, and our distribution partner enables us to combine technology, regulatory execution, and consumer access in one strategy that will accelerate impact at scale,” Dr Fielding said.

Audeara was up half a cent or 26.3 percent to 2.4 cents with 3.2 million shares traded.

ANTEOTECH

Anteotech says Seoul’s Kangshin Industrial Co Ltd will distribute its Anteo X and Ultranode battery products in South Korea.

Anteotech said Kangshin was a privately owned specialty trading and technical services company with “a strong position importing and distributing chemicals and materials ... to major global manufacturers in South Korea”.

The company said Kanghsin would market, warehouse and support its Anteo X ‘cross-linking’ product for batteries, providing local inventory and facilitating after-sales services as well as supporting its Ultranode, high silicon anode formulation technology.

Anteotech managing-director Merrill Gray said Kangshin provided the company “with an immediate, high-calibre presence in one of Asia’s most sophisticated manufacturing economies and innovative battery technology hubs”.

Anteotech was unchanged at 2.4 cents with 20.1 million shares traded.

OPYL

Opyl says it has a three-year services agreement with London’s Innovatrix Capital for the use of its Trialkey artificial intelligence (A.I.) in a clinical trial insurance product.

Earlier this year, Opyl said it would develop a product with Innovatrix to insure against the risk of clinical trial failure using its Trialkey, as an “an independent calculation agent providing its industry-leading ‘probability of success’ estimates, with 95 percent confidence intervals, at key stages of a clinical trial” (BD: Jun 18, 2025).

Today, Opyl said Trialkey would deliver its “probability of success estimates at key stages of a ... trial, directly supporting Innovatrix’s underwriting, pricing and claims functions”.

The company said it would receive a \$103,000 non-refundable retainer, a one percent fee of the risk premium for each insurance policy, and a 20 percent share of Innovatrix’s mid-term adjustment admin fees for interim probability of success re-estimates.

The company said Trialkey would be used as a calculation agent for phase I and phase II trials in Innovatrix’s Clinix insurance product.

Opyl was up 0.2 cents or 10 percent to 2.2 cents.

ARCHER MATERIALS

Archer says it will partner with the Leuven, Belgium-based Interuniversity Microelectronics Centre (IMEC) to develop its Biochip and blood potassium sensor.

Last year, Archer said it had designed a miniature version of its Biochip for applications in biotechnology; and later, said it had began experiments to detect and monitor chronic kidney disease by detecting potassium on its Biochip (BD: Mar 11, Aug 27, 2024).

Earlier this year, the company said it had integrated its graphene field effect transistor sensors with readout circuitry, a “milestone” for its at-home chronic kidney disease testing device (BD: May 29, 2025).

Today, Archer said IMEC would trial the use of its silicon-based devices such as ion-selective field effect transistors alongside its graphene Biochip device to study if silicon could “offer a faster and more scalable path to manufacturing, reducing barriers to clinical translation and commercial production”.

Archer was up 1.5 cents or 5.7 percent to 28 cents.

NEURIZON THERAPEUTICS (FORMERLY PHARMAUST)

Neurizon says it has begun manufacturing the first registration batch of NUZ-001 tablets for use in its amyotrophic lateral sclerosis (ALS) trials and regulatory submissions.

Neurizon said manufacturing would be conducted by the Bridgewater, New Jersey-based Catalent Inc and was “a key milestone towards commercialization and [US Food and Drug Administration new drug application] regulatory submission”.

The company said it was manufacturing the first of three planned registration batches, “all to be manufactured over the coming months”, with the batches to produce a minimum one to 10 scale of the intended commercial production volume of 1,400,000 tablets.

Neurizon said following manufacturing, the batches would be “placed on both long-term and accelerated stability programs to establish product shelf-life and generate data to support module 3 (quality) of the [new drug application] dossier”.

Neurizon managing-director Dr Michael Thurn said that manufacturing NUZ-001 was “a critical milestone on our path to commercial readiness and regulatory submission”.

Neurizon was unchanged at 16 cents.

TRYPTAMINE THERAPEUTICS

Tryptamine says it has a \$2.6 million loan from Perth’s Rockford Equity at 16 percent interest a year against its expected Federal Research and Development Tax Incentive.

Tryptamine said it could draw \$500,000 tranches and the loan was secured against its expected Federal Research and Development Tax Incentive for the year to June 30, 2026. The company said it expected to receive \$800,000 from the Australian Taxation Office “in the coming months” relating to eligible research and development expenditure for the year to June 30, 2024.

Tryptamine said the loan would be used for the clinical development of its TRP-8803 intravenous infused psilocin as well as other clinical activities.

Tryptamine was up 0.1 cents or three percent to 3.4 cents with 4.2 million shares traded.